fingolimod hydrochloride has been researched along with Intellectual Disability in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baghbanian, SM; Cheraghmakani, H; Nasehi, MM | 1 |
| Barker, DA; Botchwey, EA; Das, A; Lau, CM; Lin, Y; Wang, T | 1 |
2 other study(ies) available for fingolimod hydrochloride and Intellectual Disability
| Article | Year |
|---|---|
Neurodevelopmental retardation in a baby born to a multiple sclerosis patient being treated with fingolimod.
Topics: Child, Preschool; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Infant, Newborn; Intellectual Disability; Multiple Sclerosis; Pregnancy; Pregnancy Complications; Pregnancy Trimester, First; Prenatal Exposure Delayed Effects | 2019 |
Delivery of bioactive lipids from composite microgel-microsphere injectable scaffolds enhances stem cell recruitment and skeletal repair.
Topics: Abnormalities, Multiple; Animals; Bone Regeneration; Cataract; Cell Differentiation; Cell Movement; Cornea; Female; Fingolimod Hydrochloride; Gels; Hypogonadism; Intellectual Disability; Lipids; Mice; Mice, Inbred C57BL; Microcephaly; Microspheres; Optic Atrophy; Propylene Glycols; Rats; Rats, Sprague-Dawley; Sphingosine; Stem Cells; Tissue Scaffolds | 2014 |